<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We are reporting on a 47-year-old man who presented with a prolongation of the activated partial thromboplastin time (APTT) prior to orthopedic surgery </plain></SENT>
<SENT sid="1" pm="."><plain>An evaluation suggested an inhibitor when his plasma prolonged a <z:mpath ids='MPATH_458'>normal</z:mpath> control APTT upon 50:50 solution of patients with <z:mpath ids='MPATH_458'>normal</z:mpath> plasma </plain></SENT>
<SENT sid="2" pm="."><plain>The platelet-neutralizing procedure (PNP), anticardiolipin antibody, and antinuclear antibody (ANA) were positive </plain></SENT>
<SENT sid="3" pm="."><plain>Further studies revealed decreased <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor ristocetin cofactor (vWF:RCoF), <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor antigen (vWF:Ag), an inhibitor to vWF, and absent high-molecular-weight vWF multimeters </plain></SENT>
<SENT sid="4" pm="."><plain>Assays of FVIII:C, FIX, and FXI were nonparallel to the standard curve </plain></SENT>
<SENT sid="5" pm="."><plain>Intravenous immunoglobulin (IVIG) corrected the APTT, multimeric pattern, and FVIII:C by the 7th day postinfusion </plain></SENT>
<SENT sid="6" pm="."><plain>This case demonstrates the efficacy of IVIG for acquired <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e>'s syndrome (vWS) and also represents a unique combination of a <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e>-like <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> and acquired vWS in a patient without the full serological requirement for <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) </plain></SENT>
<SENT sid="7" pm="."><plain>Whether patients with acquired vWS and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> inhibitors are more or less susceptible to either a thrombotic complication or <z:mp ids='MP_0001914'>hemorrhage</z:mp> is not established </plain></SENT>
<SENT sid="8" pm="."><plain>Prospective studies for the incidence of <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> inhibitor/<z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndromes</z:e> and vWF deficiencies are needed to assess this question </plain></SENT>
</text></document>